6533b871fe1ef96bd12d22c4
RESEARCH PRODUCT
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
Christiane Windemuth-kieselbachFrederik MarméMatthias W. BeckmannErich SolomayerEva-maria GrischkeMarcus SchmidtDirk StrumbergFrank Gerhard FoersterBernd GerberPeter KlareAndreas SchneeweissVolker Moebussubject
OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drugdescription
1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |